Early decrease of T-bet plus B cells during subcutaneous belimumab predicts response to therapy in systemic lupus erythematosus patients

被引：0

作者：

La Gualana, Francesca ^{[1
]}

Olivieri, Giulio ^{[2
]}

Petriti, Begi ^{[1
]}

Picciariello, Licia ^{[3
]}

Natalucci, Francesco ^{[3
]}

Sciannamea, Maddalena ^{[1
]}

Gragnani, Laura ^{[4
]}

Basile, Umberto ^{[5
]}

Casato, Milvia ^{[1
]}

Spinelli, Francesca Romana ^{[3
]}

Stefanini, Lucia ^{[1
]}

Basili, Stefania ^{[1
]}

Visentini, Marcella ^{[1
]}

Ceccarelli, Fulvia ^{[3
]}

Conti, Fabrizio ^{[3
]}

机构：

[1] Sapienza Univ, Dept Translat & Precis Med, Viale Univ 37, I-00185 Rome, Italy

[2] Bambino Gesu Pediat Hosp, IRCCS, Res Unit Clin Immunol & Vaccinol, Rome, Italy

[3] Sapienza Univ Roma, Dipartimento Sci Clin Internist Anestesiolog & Car, Lupus Clin, Rheumatol, Viale Policlin 155, I-00161 Rome, Italy

[4] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Med Sch, Pisa, Italy

[5] Santa Maria Goretti Hosp AUSL Latina, Dept Clin Pathol, Latina, Italy

来源：

IMMUNOLOGY LETTERS | 2025年 / 272卷

关键词：

Systemic lupus erythematosus; Belimumab; T -bet plus B cells; Biomarker; MIXED CRYOGLOBULINEMIA; SELECTION; ABNORMALITIES; EFFICACY; BAFF; BLYS;

D O I：

10.1016/j.imlet.2024.106962

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Systemic lupus erythematosus (SLE) is characterized by B cell dysregulation and expansion of atypical B cells that may correlate with disease manifestations and activity. This study investigated the impact of subcutaneous (sc) Belimumab (BLM) on the peripheral B cell compartment and on the functional properties of CD21low, T-bet+ and CD11c+ atypical B cells, in 21 active SLE patients over a 12-month period. At baseline, active SLE patients displayed reduced unswitched IgM memory B cells and expansion of atypical B cells, compared to healthy donors and to SLE patients in remission. sc BLM therapy promptly restored B cell homeostasis with a reduction of T-bet+ B cells, observed early in patients responsive to therapy. These findings highlight the pathogenic role of T-bet+ B cells in SLE disease and suggest their potential utility as biomarker of clinical response.

引用

页数：10

共 46 条

[1] ANALYSIS OF THE EXPRESSION OF T-BET IN B LYMPHOCYTES OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Marasco, E.
Moneta, G. M.
Bracaglia, C.
Caiello, I.
Farroni, C.
Carsetti, R.
De Benedetti, F.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1185 - 1185
[2] Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus
Miyazaki, Yusuke
Nakayamada, Shingo
Sonomoto, Koshiro
Akio, Kawabe
Inoue, Yoshino
Okubo, Naoaki
Iwata, Shigeru
Hanami, Kentaro
Tanaka, Yoshiya
RHEUMATOLOGY, 2022, 61 (09) : 3614 - 3626
[3] Association between early immunophenotypic changes and therapeutic response of belimumab in patients with systemic lupus erythematosus
Hirano, Aiko
Fujioka, Kazuki
Kida, Takashi
Omura, Satoshi
Sofue, Hideaki
Sakashita, Aki
Sagawa, Tomoya
Isoda, Yu
Kasahara, Akiko
Sagawa, Risa
Fujii, Wataru
Seno, Takahiro
Wada, Makoto
Kohno, Masataka
Kawahito, Yutaka
LUPUS, 2023, 32 (01) : 63 - 73
[4] Efficacy and Safety of Belimumab Plus Standard Therapy in Patients With Systemic Lupus Erythematosus: A Meta-analysis
Wei, Li-qiang
Liang, Yong-gang
Zhao, Yong
Liang, Hui-tao
Qin, Dong-chun
She, Ming-cong
CLINICAL THERAPEUTICS, 2016, 38 (05) : 1134 - 1140
[5] Copy number variations of Interleukin-12B and T-bet are associated with systemic lupus erythematosus
Yu, Bo
Shao, Yong
Yue, Xupeng
Zhang, Jie
Guan, Ming
Wan, Jun
Zhang, Wei
RHEUMATOLOGY, 2011, 50 (07) : 1201 - 1205
[6] Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus
Ginzler, Ellen M.
Wallace, Daniel J.
Merrill, Joan T.
Furie, Richard A.
Stohl, William
Chatham, W. Winn
Weinstein, Arthur
McKay, James D.
McCune, W. Joseph
Zhong, Z. John
Freimuth, William W.
Petri, Michelle A.
JOURNAL OF RHEUMATOLOGY, 2014, 41 (02) : 300 - 309
[7] Belimumab promotes negative selection of activated autoreactive B cells in systemic lupus erythematosus patients
Huang, Weiqing
Quach, Tam D.
Dascalu, Cosmin
Liu, Zheng
Leung, Tungming
Byrne-Steele, Miranda
Pan, Wenjing
Yang, Qunying
Han, Jian
Lesser, Martin
Rothstein, Thomas L.
Furie, Richard
Mackay, Meggan
Aranow, Cynthia
Davidson, Anne
JCI INSIGHT, 2018, 3 (17):
[8] Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab
Regola, Francesca
Piantoni, Silvia
Lowin, Torsten
Archetti, Silvia
Reggia, Rossella
Kumar, Rajesh
Franceschini, Franco
Airo, Paolo
Tincani, Angela
Andreoli, Laura
Pongratz, Georg
FRONTIERS IN PHARMACOLOGY, 2019, 10
[9] Phospholipase D4 as a signature of toll-like receptor 7 or 9 signaling is expressed on blastic T-bet plus B cells in systemic lupus erythematosus
Yasaka, Ken
Yamazaki, Tomohide
Sato, Hiroko
Shirai, Tsuyoshi
Cho, Minkwon
Ishida, Koji
Ito, Koyu
Tanaka, Tetsuhiro
Ogasawara, Kouetsu
Harigae, Hideo
Ishii, Tomonori
Fujii, Hiroshi
ARTHRITIS RESEARCH & THERAPY, 2023, 25 (01)
[10] THE INCREASE OF CIRCULATING CD4+ T-CELLS WITH EFFECTOR PHENOTYPE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS MAY BE REVERTED AFTER BELIMUMAB THERAPY
Piantoni, S.
Scarsi, M.
Andreoli, L.
Dall'Ara, F.
Zanola, A.
Tincani, A.
Airo, P.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : S25 - S25

← 1 2 3 4 5 →